7.41
+3.20%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kazia Therapeutics Ltd ADR
Its shares trade under the ticker KZIA. It has been listed since 6 January 1999. In the fiscal year to 30 June 2025, it reported revenue of $29,523 and a net loss of $14.6m. At that date it held total assets of $4.3m and shareholders' equity of −$5.8m.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Jan 1999
- Employees
- 6
- Website
- kaziatherapeutics.com ↗
- Head office
- THREE INTERNATIONAL TOWERS LEVEL 24,, SYDNEY NSW, 2000
- Incorporated in
- C3
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kazia Therapeutics leads in oncology-focused biotechnology with paxalisib in Phase II/III trials for glioblastoma treatment.
- Collaborations with Genentech Inc. and QIMR Berghofer Medical Research Institute enhance clinical development capabilities.
- Six employees efficiently manage multiple clinical trials across various cancer types including CNS lymphoma and breast cancer.
Weaknesses
- Limited employee count of six restricts operational capacity for rapid expansion.
- US listing on 6 January 1999 may indicate outdated market presence for a biotech firm.
- Sydney headquarters location might limit access to major biotech hubs in the US or Europe.
Opportunities
- Paxalisib's Phase II/III trials for glioblastoma present significant market potential in oncology treatments.
- EVT801 in Phase I trials for ovarian cancer could open new revenue streams in solid tumor therapies.
- Collaborations with Simcere Pharmaceutical Group Ltd and Evotec SE may lead to expanded global market reach.
Threats
- Competition from established oncology drugs could delay paxalisib's market entry.
- Regulatory hurdles in the US market may prolong clinical trial timelines for new therapies.
- Financial constraints due to limited employee numbers could impact research and development funding.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.